Severe Combined Immunodeficiency 

  • Author: Elizabeth A Secord, MD; Chief Editor: Michael A Kaliner, MD   more...
 
Updated: May 5, 2009
 

Background

Severe combined immunodeficiency (SCID) is a disorder that results from any of a heterogenous group of genetic conditions affecting the immune system. SCID leads to severe T- and B-cell dysfunction. Without intervention, the T- and B-cell dysfunction usually results in severe infection and death in children by age 2 years.

The most common genetic condition responsible for SCID is a mutation of the common gamma chain of the interleukin (IL) receptors shared by the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 (T-cell-, natural killer [NK] cell-, B-cell+).[1] This protein is encoded on the X chromosome; therefore, this variant of SCID is X-linked (and is sometimes referred to as X-linked SCID). These patients account for approximately 50% of all patients with SCID.

Autosomal recessive SCID (formerly known as Swiss-type agammaglobulinemia) includes Janus-associated kinase 3 (JAK3; T-, NK-, B+) deficiency,[2, 3, 4, 5] adenosine deaminase (ADA) deficiency (T-, B-, NK+/-),[6] bare lymphocyte syndrome (a somewhat milder SCID),[7, 8, 9] zeta chain–associated protein (ZAP)-70 deficiency,[10] reticular dysgenesis, IL-7 receptor α deficiency, recombination-activating gene (RAG)-1 and RAG-2 deficiency (T-, B-, NK+),[11] ligase 4 deficiency (T-, B-, NK+),[12] and CD45 deficiency.[13]

Several deficiencies of the CD3 complex (CD3 γ, ε, δ, and ζ) are associated with SCID.[14, 15]Omenn syndrome is associated with Artemis defect.[16] Purinenucleotide phosphorylase (PNP) deficiency and IL-2 deficiency are severe enough in nature to be classified as SCID, and other defects are identified every year.[17]

These are the most common and best characterized forms of SCID, but not all of the genetic conditions leading to SCID are well characterized. Infants with SCID usually present with infections that are secondary to the lack of T-cell function (eg, Pneumocystis jiroveci pneumonia [PCP], systemic candidiasis, generalized herpetic infections, severe failure to thrive secondary to gut infections/diarrhea). Graft versus host disease (GVHD) from nonirradiated blood products is an important cause of morbidity. SCID is considered a pediatric emergency and requires prompt workup and treatment.

Next

Pathophysiology

The pathophysiology and molecular biology vary; however, the lack of T-cell and B-cell function is the common endpoint in all forms of SCID.

Cellular hallmarks that help differentiate between various forms of SCID are as follow:

  • X-linked SCID: Lymphopenia occurs primarily from the absence or near absence of T cells (CD3+) and natural killer (NK) cells. Variable levels of B cells occur, which do not make functional antibodies.
  • JAK3 deficiency: Lymphopenia occurs primarily from the absence or near absence of T cells (CD3+) and NK cells. Normal or high levels of B cells occur, which do not make functional antibodies.
  • ADA deficiency: Lymphopenia occurs from the death of T and B cells secondary to the accumulation of toxic metabolites in the purine salvage pathway. Functional antibodies are decreased or absent.
  • ZAP-70 deficiency: Lymphopenia occurs because of the absence of CD8+ T cells. As in all types of SCID, no antibody formation is present.
  • Reticular dysgenesis: Lymphopenia occurs from the absence of myeloid cells in the bone marrow. Red blood cells and platelets are present and functioning.
  • Omenn syndrome: Normal or elevated T-cell numbers are present, but these are of maternal, not fetal, origin. The B cells are usually undetectable, NK cells are present, and the total immunoglobulin level is markedly low with poor antibody production. Eosinophils are elevated, and the total serum immunoglobulin E (IgE) level is elevated.

Combined immune deficiencies that are sometimes severe enough to be classified as SCID are as follow:

  • PNP deficiency: Lymphopenia occurs from the death of T cells secondary to the accumulation of toxic metabolites in the purine salvage pathway. This deficiency differs from ADA deficiency because circulating B cells are normal in number. However, B-cell function is poor, as evidenced by the lack of antibody formation. PNP deficiency can be severe enough to be classified as SCID.
  • Bare lymphocyte syndrome: The lymphocyte count is normal or mildly reduced, the CD4+ T cells are decreased, and the CD8+ T cell numbers are normal or mildly increased. The B-cell numbers are normal or mildly decreased, but the ability to make antibodies is decreased. Bare lymphocyte syndrome is sometimes classified as SCID.
  • IL-2 deficiency: Normal, or near normal, numbers of T cells exist (both CD4+ and CD8+). The T cells fail to proliferate in vitro when stimulated with mitogens, unless IL-2 is added to the culture medium. The production of functional antibody is decreased. IL-2 deficiency may be severe enough to be classified as SCID.

Molecular abnormalities in various forms of SCID are as follow:

  • X-linked SCID: Mutation of the common gamma chain (IL-2R, IL-4R, IL-7R, IL-9R, IL-15R, IL-21R) of the IL receptors occurs, resulting in loss of cytokine function. Loss of IL-2R function leads to the loss of a lymphocyte proliferation signal. Loss of IL-4R function leads to the inability of B cells to class switch. Loss of IL-7R function leads to the loss of an antiapoptotic signal, resulting in a loss of T-cell selection in the thymus. Loss of IL-7R function is also associated with the loss of a T-cell receptor (TCR) rearrangement. Loss of IL-15R function leads to the ablation of NK cell development.[1, 2, 3]
  • JAK3 deficiency: JAK3 is a protein tyrosine kinase (PTK) that associates with the common gamma chain of the IL receptors. Deficiency of this protein results in the same clinical manifestations as those of X-linked SCID.[4, 5]
  • IL-2 production deficiency: The exact molecular defect is unknown, but it is often associated with other cytokine production defects.
  • Bare lymphocyte syndrome: This is a deficiency of major histocompatibility complex (MHC). MHC type II is decreased on mononuclear cells. MHC type I levels may be decreased, or MHC type I may be absent. The defect occurs in a gene regulating expression of MHC type II.[7, 8]
  • ZAP-70 deficiency: A mutation occurs in the gene coding for this tyrosine kinase, which is important in T-cell signaling and is critical in positive and negative selection of T cells in the thymus. A selection absence of CD8+ T cells and an abundance of nonfunctioning CD4+ T cells occurs. ZAP-70 is apparently needed in the selection of CD8+ T cells and is necessary for T cell functioning, thus the nonfunctioning CD4+ cells.[10]
  • Omenn syndrome: Mutations that impair the function of immunoglobulin and TCR recombinase genes (ie, RAG1, RAG2 genes) are responsible for this syndrome. These include the Artemis mutation (enzyme that opens DNA hairpin during variable diversity joining [VDJ] rearrangement) and RAG1 and RAG2 deficiencies.[11, 16]
  • ADA deficiency: ADA is an enzyme that breaks down purines. When it is absent, deoxyadenosine triphosphate (dATP) builds up and inhibits the enzymes necessary for lymphocyte proliferation. It causes B-, T-, and NK-cell deficiency.[6]
Previous
Next

Epidemiology

Frequency

United States

SCID occurs in approximately 1 in 50,000-75,000 live births. The incidence was previously reported at approximately 1 in 100,000, but improved early identification of affected subjects revealed that the true incidence is higher than previously believed. Approximately 50% of all SCID cases are X-linked (ie, mutation of the common gamma chain). The remaining 50% are various forms of autosomal recessive SCID. Approximately 25% of the patients with an autosomal recessive SCID are JAK3 deficient, and 40% are ADA deficient. The other disorders make up the remaining 35% of autosomal recessive patients.

International

International frequency is similar to that of the United States. X-linked SCID, like other X-linked disorders, has a higher frequency in populations with increased consanguinity.

Mortality/Morbidity

Without treatment, death from infection usually occurs within the first 2 years of life. GVHD from maternal cell engraftment can occur in any SCID case. The transfusion of nonirradiated blood products is an important cause of GVHD in all forms of SCID.

Race

No racial predisposition exists for most forms of SCID, but most patients with ZAP-70 deficiency and CD3 δ are Mennonites. The Artemis gene deficiency is seen predominately in Navajo and Apache Native Americans.

Sex

Approximately 50% of SCID cases are X-linked (ie, occurring only in males). No sexual predisposition is associated with autosomal recessive SCID.

Age

The average age at the onset of symptoms is 2 months.

Previous
 
 
Contributor Information and Disclosures
Author

Elizabeth A Secord, MD  Clinical Associate Professor, Department of Pediatrics, Division of Pediatric Immunology, Wayne State University

Elizabeth A Secord, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American College of Allergy, Asthma and Immunology, and American Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Eyal Oren, MD  Consulting Staff, Institute for Asthma and Allergy

Eyal Oren, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology and American College of Allergy, Asthma and Immunology

Disclosure: Nothing to disclose.

Specialty Editor Board

Charles H Kirkpatrick, MD  Professor of Medicine and Immunology, University of Colorado School of Medicine; Director of Adult Immune Deficiency Program, Department of Medicine, University of Colorado Health Sciences Center; Consulting Staff, Department of Medicine, National Jewish Medical and Research Center

Charles H Kirkpatrick, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Physicians, American Federation for Clinical Research, American Society for Clinical Investigation, and Clinical Immunology Society

Disclosure: Lev Pharmaceuticals Consulting fee Consulting

Francisco Talavera, PharmD, PhD  Senior Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

Stephen C Dreskin, MD, PhD  Director of Allergy, Asthma, and Immunology Practice, Professor of Medicine, Departments of Internal Medicine and Immunology, University of Colorado Health Sciences Center

Stephen C Dreskin, MD, PhD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association for the Advancement of Science, American Association of Immunologists, American Association of Neuropathologists, American Association of Ophthalmic Pathologists, American Association of Oral and Maxillofacial Surgeons, American College of Allergy, Asthma and Immunology, Clinical Immunology Society, and Joint Council of Allergy, Asthma and Immunology

Disclosure: Genentech Consulting fee Consulting

Timothy D Rice, MD  Associate Professor, Departments of Internal Medicine and Pediatrics and Adolescent Medicine, Saint Louis University School of Medicine

Timothy D Rice, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Physicians

Disclosure: Nothing to disclose.

Chief Editor

Michael A Kaliner, MD  Clinical Professor of Medicine, George Washington University School of Medicine; Chief, Section of Allergy and Immunology, Washington Hospital Center; Medical Director, Institute for Asthma and Allergy

Michael A Kaliner, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Allergy, Asthma and Immunology, American Society for Clinical Investigation, American Thoracic Society, and Association of American Physicians

Disclosure: Abbott Consulting fee Consulting; Alcon Consulting fee Consulting; Glaxo Consulting fee Consulting; Greer Consulting fee Consulting; Sanofi Consulting fee Consulting; Schering Consulting fee Consulting; Teva Consulting; Meda Honoraria Speaking and teaching

References
  1. Fischer A. Severe combined immunodeficiencies. Immunodefic Rev. 1992;3(2):83-100. [Medline].

  2. Uribe L, Weinberg KI. X-linked SCID and other defects of cytokine pathways. Semin Hematol. Oct 1998;35(4):299-309. [Medline].

  3. Hong R. Disorders of the T cell system. In: Stiehm ER, ed. Immunologic Disorders in Infants and Children. 4th ed. Philadelphia, Pa: WB Saunders; 1996:339-408.

  4. Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. Sep 7 1995;377(6544):65-8. [Medline].

  5. Candotti F, O'Shea JJ, Villa A. Severe combined immune deficiencies due to defects of the common gamma chain-JAK3 signaling pathway. Springer Semin Immunopathol. 1998;19(4):401-15. [Medline].

  6. Hirschhorn R, Vawter GF, Kirkpatrick JA Jr, Rosen FS. Adenosine deaminase deficiency: frequency and comparative pathology in autosomally recessive severe combined immunodeficiency. Clin Immunol Immunopathol. Sep 1979;14(1):107-20. [Medline].

  7. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol. 2001;19:331-73. [Medline].

  8. DeSandro A, Nagarajan UM, Boss JM. The bare lymphocyte syndrome: molecular clues to the transcriptional regulation of major histocompatibility complex class II genes. Am J Hum Genet. Aug 1999;65(2):279-86. [Medline].

  9. Mach B, Steimle V, Reith W. MHC class II-deficient combined immunodeficiency: a disease of gene regulation. Immunol Rev. Apr 1994;138:207-21. [Medline].

  10. Elder ME, Lin D, Clever J, et al. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science. Jun 10 1994;264(5165):1596-9. [Medline].

  11. Villa A, Santagata S, Bozzi F, Imberti L, Notarangelo LD. Omenn syndrome: a disorder of Rag1 and Rag2 genes. J Clin Immunol. Mar 1999;19(2):87-97. [Medline].

  12. O'Driscoll M, Cerosaletti KM, Girard PM, et al. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell. Dec 2001;8(6):1175-85. [Medline].

  13. Kung C, Pingel JT, Heikinheimo M, et al. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat Med. Mar 2000;6(3):343-5. [Medline].

  14. Rieux-Laucat F, Hivroz C, Lim A, et al. Inherited and somatic CD3zeta mutations in a patient with T-cell deficiency. N Engl J Med. May 4 2006;354(18):1913-21. [Medline].

  15. Dadi HK, Simon AJ, Roifman CM. Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency. N Engl J Med. Nov 6 2003;349(19):1821-8. [Medline].

  16. Ege M, Ma Y, Manfras B, Kalwak K, Lu H, Lieber MR. Omenn syndrome due to ARTEMIS mutations. Blood. Jun 1 2005;105(11):4179-86. [Medline].

  17. Hitzig WH, Landolt R, Müller G, Bodmer P. Heterogeneity of phenotypic expression in a family with Swiss-type agammaglobulinemia: observations on the acquisition of agammaglobulinemia. J Pediatr. Jun 1971;78(6):968-80. [Medline].

  18. Chan K, Puck JM. Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol. Feb 2005;115(2):391-8. [Medline].

  19. Lebet T, Chiles R, Hsu AP, Mansfield ES, Warrington JA, Puck JM. Mutations causing severe combined immunodeficiency: detection with a custom resequencing microarray. Genet Med. Aug 2008;10(8):575-85. [Medline].

  20. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. Jan 29 2009;360(5):447-58. [Medline].

  21. Booth C, Hershfield M, Notarangelo L, et al. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol. May 2007;123(2):139-47. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.